Our companies

Funded by the Knut & Alice Wallenberg foundation, the Human Protein Atlas was initiated in 2003 by Swedish researchers to map the entire human proteome. Based on strong research demand, Atlas Antibodies was formed 2006 to commercialize the over 20,000 antibodies developed within the project. Today, the product suite encompasses polyclonal and monoclonal antibodies and mass spec standards.

2021, the company acquired Swiss-based evitria, a high-quality customized recombinant antibody provider, and HistoCyte Laboratories, a global leader in cell line controls. These acquisitions brought together a leading provider of highly validated research antibodies with a front-runner in the field of customized recombinant antibody expression and a provider of innovative cell line materials. Together, the joint entity serves a broad customer group, from research and academic labs, to hospital labs, small biotech, and larger pharmaceuticals.

During the past ten years, the joint company has experienced double digit annual growth rates. The company’s products and services are available across the globe, with current sales evenly split between North America and Europe, with a growing presence in APAC.

What excites us

• Deep scientific roots, dedicated to advance discovery  
• A unique and comprehensive portfolio of high-quality products and services  
• Attractive opportunities for profitable growth, fueled by favorable market trends  
• Continued M&A opportunities

Founded with only a handful of employees in Winamac, Indiana, but with a spirit of entrepreneurship and a commitment to improve the lives of people with disabilities, the company has thrived for close to 50 years. Today, BraunAbility is the market leader in automobile mobility products for people with disabilities, and among the innovations is the first SUV for people with disabilities. BraunAbility has one of the largest product portfolios, an extensive dealer network and by far the largest market share. The original handful of employees has, over the years, grown to over a thousand and the company now offers a portfolio of complex products. Ralph built the company focusing on quality, safety and innovation – still the cornerstones of the business.

Today, BraunAbility is proud to provide freedom, mobility and independence to millions of wheelchair user across the globe, and will continue to create new, high-quality products that allow people with physical disabilities to participate fully and actively in life. Patricia Industries acquired BraunAbility in September 2015.

What excites us

• Market leader in mobility transportation and safety solu tions for people with disabilities and mobility challenges
• Organic growth potential in core markets supported by favorable demographic trends
• Multiple opportunities to grow the business through new product development, entry into new geographies, and acquisitions in core and adjacent markets
• Market-leading innovation capabilities that will enable a successful transition to electric and autonomous vehicles in the future

Founded in 1967 by Ray Laborie, Laborie has been a pioneer and market leader in urodynamic systems for several decades. In 1984, Laborie became the first manufacturer to commercialize a computerized urodynamic system. The company subsequently established a market-leading position in disposables used with its systems. Laborie remained a family business until 2012, and has since focused on expanding its offering to adjacent product verticals and therapeutic areas while keeping the innovative spirit and culture established by its founder.

In recent years, Laborie has solidified its leadership through the introduction of new diagnostic and therapeutic products, and it has integrated its supply chain and market channel. Laborie’s business benefits from market trends, including an aging population and increased awareness and diagnosis of the conditions addressed by its products.

Today, Laborie has a global infrastructure for manufacturing, development and commercialization, and leverages this platform to further expand and grow its business. In addition to its leading urodynamic systems offering, Laborie has rapidly grown in the gastrointestinal diagnostics market and will disrupt the high resolution diagnostic GI market with new technology that leverages core patented pressure-sensing technology utilized in its urology equipment and consumable products.

Patricia Industries acquired Laborie in August 2016 and owns more than 98% of the company, with management owning the remaining equity.

What excites us

• Innovative, differentiated product portfolios across each of Laborie’s core markets
• Strong organic growth fueled by new product development and global expansion
• Continued scope for strategic acquisitions within and beyond Laborie’s core markets to add product portfolio and commercial scale as well as new technologies

Mölnlycke, headquartered in Gothenburg, Sweden, is a world-leading specialist provider and innovator of single-use wound care and surgical products. It has a long history of challenging the status quo and, through innovation, create advanced wound care products that reduce the healing time and suffering of patients. This approach has made Mölnlycke the market leader within advanced wound care dressings. In addition, Mölnlycke is a pioneer in the field of dressings and other products for the prevention of wounds, such as pressure ulcers. Mölnlycke also makes the operating room more efficient with innovative and safe surgical solutions. Cutting-edge and cost-efficient products have made Mölnlycke the company it is today.

Over the years the entrepreneurial and innovative spirit that characterizes Mölnlycke has resulted in an R&D-department that is committed to bringing new, innovative products to the market. Also, demographic factors, such as an aging population and an increase in surgical procedures, have created a greater demand for high-quality medical products. This has in turn resulted in growth and improvements further reinforcing our offering to the market. Mölnlycke has grown strongly since it was acquired over the years. Successful acquisitions have also been made to complement the product offering.

What excites us

• Strong market position in Wound Care with consistent outperformance vs. peers supported by products with strong health economics 
• Ability to continuously expand the offering through organic and inorganic innovation 
• Driving growth through commercial excellence and invest ments in innova tion while actively exploring complementary acquisitions to accelerate growth 
• Unwavering commitment to sustainability shapes the future of healthcare and serves as a powerful business driver that builds trust, secures strategic deals and deepens long-term partnerships

Nova Biomedical was formed from the merger of Advanced Instruments (acquired in 2020) and Nova Biomedical (acquired in 2025) - two businesses that have each been dedicated to increasing productivity and ensuring quality in the biopharmaceutical, clinical and food & beverage markets for many decades.

Nova Biomedical designs and commercializes innovative, differentiated analytical instrumentation products that help their global customer base improve product quality and safety, meet regulatory requirements, improve patient care, and reduce costs. The company's products are used in over 100 countries by leading biopharmaceutical companies, hospitals, and food & beverage products.

Nova Biomedical has multiple organic and non-organic opportunities for long-term profitable growth due to its innovative, differentiated product portfolio, strong and durable underlying growth rates in each of the company's core markets, and numerous attractive add-on acquisition opportunities.

What excites us

• Culture and track record of customer-focused innovation
• Strong product portfolios across the attractive biopharma and clinical markets
• Global presence with direct commercialization in key geog raphies
• Strong, resilient and predictable financial profile with his tory of consistent organic growth
• Scope for continued add-on acquisitions within the core biopharma and clinical markets as well as adjacent analyti cal instrumentation markets across other industries

Advanced rehab mobility solutions are not only key components that improve the quality of life for people with functional disabilities, but also an essential part of medical treatment. The complex and special nature of rehab technology demands substantial investments in research and development, which is at the core of Permobil’s business. All chairs from Permobil are built to order and designed to cater to the specific medical needs of the individual. In the endeavor to build top-quality powered and manual wheelchairs, Permobil constantly strives to innovate. In doing so the company is pushing the boundaries of what is possible, resulting in many “firsts” in the industry.

Today, Permobil’s products are sold in more than 70 countries worldwide. North America and Europe are its largest markets, but Permobil is proud that its innovative solutions are being made available to more and more disabled people around the World.

Since Patricia Industries acquired Permobil in 2013, the company has been growing strongly on its own as well as through select acquisitions of product market leaders and distributors that help us become even more relevant to our customers.

What excites us

• A strong mission to improve quality of life for users through innovation in mobility solutions
• Rapid innovation based on user-centricity that fuels com petitiveness
• A strong outlook as a global leading provider of advanced mobility solutions with attractive opportunities for contin ued profitable growth
• Strategic add-on acquisitions to strengthen the product portfolio and broaden global reach

Automation is transforming production processes around the globe, driven by the continuous strive for efficient production and improved quality. The average global robot density increased to 162 robot units per 10,000 employees in 2023, up from 74 units in 2016 (according to IFR). The technological breakthroughs in robotics and connectivity brings multiple opportunities, such as opening-up new industries for automation and facilitating fully digital business models, requiring Piab’s smart and line-critical solutions.

The company will continue to invest in product development to be at the forefront of innovation and deliver smart automation solutions to help its customers improve productivity and working environments. Piab Group will also continue to expand its geographic end markets and look for strategic add-on acquisitions to accelerate growth and expand into adjacent segments.

Piab has had a double-digit sales growth over the last years, through a combination of organic growth and acquisition of niche players to further strengthen the product offering and geographical footprint.

Piab’s vision is an automated world where no resources are wasted, and no humans are injured.

What excites us

• An innovative culture and application expertise continue to drive the development of leading products in performance, energy efficiency, and intelligent features
• Significant growth potential, underpinned by the global automation trend
• Technological breakthroughs in robotics and connectivity bring multiple opportunities for new applications and increased adoption
• Accelerated growth potential by entering new end- markets and geographies, organically and through strategic acquisitions

Sarnova provides a wide range of highly differentiated, mission-critical products and value added services to thousands of customers in the emergency preparedness and acute care markets, including fire departments, ambulance companies, law enforcement, the federal government, and hospital emergency, critical care and neonatal intensive care departments.

Over the past ten years, Sarnova has completed eight acquisitions to expand its suite of medical products and services. Patricia Industries acquired Sarnova in April 2018.

What excites us

• Attractive long-term profitable growth potential as a leading provider of specialty medical products and services for the emergency preparedness, cardiac response, and respira tory markets in the U.S.
• Accelerated adoption of Sarnova’s private label solutions alongside continued investments in warehouse digitaliza tion and automation present exciting opportunities
• Sarnova continue to evaluate strategic acquisition opportu nities to strengthen the existing businesses and to expand into attractive adjacencies, leveraging its deep customer relationships and strong market position to further serve the existing customer base with new products, technology solutions, and services

Vectura is a real estate company focusing on the commercial segment with the USP of developing innovation clusters within both life science and sustainable mobility. With a deep understanding of its customers’ businesses and needs, Vectura strives to support its customers’ operations by providing the right prerequisites with innovative and sustainable properties. Vectura manages all steps in the property value chain, from land acquisition to property development and management. The company put great emphasis on long term relationships with customers and partners, to facilitate sustainable environmental, social and economic solutions that contribute to society.

Today, Vectura’s property portfolio consist of several projects under development, including Forskaren (life science cluster in Hagastaden, Stockholm) and Bromma Sjukhus. In addition, Vectura has entered a JV with Next Step that develops two innovation clusters in Gothenburg: GoCo Health Innovation City (life science cluster in Mölndal) and Volvo Torslanda (sustainable mobility cluster in Torslanda).

What excites us

• The focus on innovation clusters to enable cooperation between research, academia and industry offers attractive long-term growth opportunities
• Strong ability to execute on the project pipeline and to source additional growth opportunities
• A people-first culture that collaborates with tenants to pioneer sustainable solutions for the future

In 2000, 3 Skandinavien, owned by Investor AB and CKHH (formerly Hutchison Whampoa), was awarded one of the four Swedish 3G licenses and began building a greenfield 3G network. Supported by the rapidly increasing availability of smartphones and customers wanting fast and reliable data everywhere, 3 Scandinavia has benefited greatly from its state-of-the-art mobile network, innovativeness and competitive service offering. Because the company is at the forefront of delivering fast data, it has benefited from high usage and increased customer demand. The company has consistently gained significant market share in both Sweden and Denmark by constantly challenging the status quo with innovative services and solutions.

Today, 3 Skandinavien has more than three million subscribers. Thanks to its strong service focus and cost-efficient structure, it has grown rapidly over the years and generated strong profit and cash flow. There is great potential for the company to continue to grow, both in the consumer and enterprise markets.

What excites us

• With the rollout of 5G, Tre Skandinavien will remain at the forefront of providing customers with high-quality and innovative services such as Fixed Wireless Access and high-speed wireless broadband via the 5G network
• With a strong, solution-oriented mindset at the core of everything – Tre Skandinavien constantly improve to serve the customers better

The majority of these holdings are in the U.S. and we typically hold minority shares with a variety of shareholder rights attached. While some of these holdings could be attractive, our ambition is to exit most of them in a way that creates value, and then reinvest in subsidiaries.